This project aims to commercialize a novel device for early and precise diagnosis of arthritic diseases in finger joints. Arthritis is a devastating disease with high prevalence and high personal and societal costs. The burden can be significantly reduced by early and targeted treatment, ideally as soon as the first symptoms occur. However, clinicians lack appropriate diagnostic tools and struggle with early and precise diagnosis. Lucid addresses this need as it is a diagnostic device for screening individuals with recent onset of joint pain and for monitoring of treatment in diagnosed patients. Lucid employs hyperspectral imaging (HSI) technology and provides high resolution spectral images from which superior diagnostic information about the diseased joint is derived. The examination is rapid, non-invasive, does not require experienced operator and subjective interpretation of the data. The technology has been jointly developed by NTNU and Norsk Elektro Optikk AS (NEO). Lucid will be a new diagnostic device for rheumatologists and orthopedic surgeons in hospitals. Therefore, clinical testing and benchmarking will be a major objective of this project. The acquired patient data will be used to optimize and further develop the diagnostic algorithms as well as a decision-making system. The functionality of the existing prototype will be improved to allow smooth utilization in the clinic.
Project leader: Sabina P. Strand
Institution: NTNU TECHNOLOGY TRANSFER AS